The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists ...
DELiveri®, a high-throughput screening platform for RNA therapeutics, ensures precise delivery with reduced toxicity across a wide range of cell types. Explore a case study on two membrane proteins ...